Category: Assay Development and Screening
An electrochemiluminescent (ECL) assay using Meso-Scale Discovery (MSD) technology was developed to detect antibodies against a cell-surface target. Instead of relying on recombinantly expressed extra-cellular domain proteins (ECD) of this target or flow cytometry, we used cell membrane preparations (membrane preps) derived from cell lines that have been transfected to overexpress this target. Membrane preps were coated onto MSD High Bind plates and samples were analyzed using an ELISA-like assay format. The same samples were also analyzed by flow cytometry using the same cell line. The results show that flow cytometry assay identified 5 hits, while the MSD assay identified 17, including 4 of the 5 identified by flow cytometry. This assay format also significantly reduces the cell culture burden and time needed to screen the same number of samples. Screening times are 30 minutes per plate using the Intellicyt HTFC and approximately 1.5 minutes per plate using the MSD SECTOR S600. This newly developed ECL method has leveraged the speed and sensitivity of the MSD platform while virtually eliminating the high background signal historically seen with membrane prep ELISAs making this method a truly high-throughput alternative to flow cytometry screening.
Philip Gorman– Scientist IV - Biotherapeutics Discovery, Boehringer Ingelheim Pharmaceuticals Inc, Ridgefield, CT
Scientist IV - Biotherapeutics Discovery
Boehringer Ingelheim Pharmaceuticals Inc
I graduated UCONN in 1999 with a BS in Physiology/Neurobiology and completed my Master's Degree in Molecular Biology at Southern CT State University in 2007. I have been working in Immunology in the Pharmaceutical industry since 2006.